Redica Systems

Trends

Recent Statement Regarding ARB Recalls

August 29, 2019

AveXis’s New Gene Therapy Approved but New Questions Are Raised

August 14, 2019

Enforcement

Review of the Office of Generic Drugs’ 2018 Annual Report

July 25, 2019

MHRA’s “Right Environment”

July 18, 2019

Trends

Analysis of CDER Report on Pharmaceutical Quality

July 11, 2019

How Mindful Leadership Supports Data Integrity

June 27, 2019

Trends

How Small Pharma Firms Can Prepare for a GMP Inspection in 2019

June 13, 2019

Data Integrity Trends in 483s and Warning Letters: Part 3

May 30, 2019

Trends

Data Integrity Trends in 483s and Warning Letters: Part 2

May 24, 2019

Trends

Data Integrity Trends in 483s and Warning Letters: Part 1

May 16, 2019

Press Release

Govzilla and FOI Services Announce Strategic Partnership

April 18, 2019

Enforcement

Why Did McKesson Receive the First DSCSA Warning Letter?

February 15, 2019

FDA Form 483: A Helpful Guide to Proactive Compliance

February 5, 2019

Enforcement

FDA Cites Part 11 in Clinical Trial

January 2, 2019

FINAL Part 3: Who’s Who? Seeing CROs Clearly.

December 12, 2018

Part 2: Who’s Who? Seeing CROs Clearly.

December 5, 2018

Part 1: Who’s Who? Seeing CROs Clearly.

November 29, 2018

Trends

FINAL Part 2: How to Stop the Data Integrity Excuses

November 15, 2018